Insulet (NASDAQ:PODD) Price Target Cut to $213.00 by Analysts at Raymond James

Insulet (NASDAQ:PODD - Get Free Report) had its target price dropped by equities researchers at Raymond James from $218.00 to $213.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an "outperform" rating on the medical instruments supplier's stock. Raymond James' target price points to a potential upside of 28.39% from the stock's current price.

A number of other equities analysts have also issued reports on the company. JPMorgan Chase & Co. raised their target price on Insulet from $190.00 to $225.00 and gave the stock an "overweight" rating in a research note on Friday, February 23rd. Jefferies Financial Group raised their target price on Insulet from $255.00 to $260.00 and gave the stock a "buy" rating in a research note on Friday. Stifel Nicolaus lifted their price objective on Insulet from $163.00 to $208.00 and gave the company a "hold" rating in a research note on Monday, February 5th. Barclays reduced their price objective on Insulet from $214.00 to $213.00 and set an "equal weight" rating for the company in a research note on Monday, February 26th. Finally, Piper Sandler reduced their price objective on Insulet from $250.00 to $230.00 and set an "overweight" rating for the company in a research note on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $240.25.

Insulet Stock Down 6.6 %

NASDAQ PODD traded down $11.63 on Friday, hitting $165.90. The stock had a trading volume of 3,116,238 shares, compared to its average volume of 686,995. The business's fifty day moving average price is $170.59 and its 200 day moving average price is $181.63. The stock has a market cap of $11.62 billion, a price-to-earnings ratio of 57.01, a price-to-earnings-growth ratio of 3.18 and a beta of 1.00. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62. Insulet has a 52-week low of $125.82 and a 52-week high of $331.65.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.34. The firm had revenue of $441.70 million during the quarter, compared to analysts' expectations of $424.05 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The business's quarterly revenue was up 23.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.23 EPS. Equities research analysts anticipate that Insulet will post 3.08 earnings per share for the current year.

Insider Transactions at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the transaction, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.47% of the company's stock.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently modified their holdings of PODD. Acadian Asset Management LLC increased its position in shares of Insulet by 1,470.9% during the first quarter. Acadian Asset Management LLC now owns 68,209 shares of the medical instruments supplier's stock worth $11,684,000 after acquiring an additional 63,867 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier's stock valued at $1,405,328,000 after purchasing an additional 169,506 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Insulet by 113.8% during the 1st quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier's stock valued at $1,140,000 after buying an additional 3,539 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp grew its position in shares of Insulet by 246.2% during the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 135,547 shares of the medical instruments supplier's stock worth $23,168,000 after buying an additional 96,390 shares in the last quarter. Finally, Scout Investments Inc. increased its stake in shares of Insulet by 178.9% in the first quarter. Scout Investments Inc. now owns 144,606 shares of the medical instruments supplier's stock worth $24,308,000 after buying an additional 92,762 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.